Plain-English translation of NCT07049055 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new experimental treatment called /GC for people with advanced pancreatic cancer that has stopped responding to first-line chemotherapy. The treatment uses tiny particles called nanocells designed to deliver cancer-fighting drugs directly to tumor cells while also boosting your immune system. You would receive this medication alongside two standard chemotherapy drugs ( and nab-paclitaxel) that are already used to treat pancreatic cancer.
Pancreatic cancer is very difficult to treat, and many patients' cancers stop responding to standard chemotherapy over time. This trial exists to see whether a newer approach—using nanocells to target cancer cells more precisely and activate the immune system—might work better than chemotherapy alone for people whose disease has progressed.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new nanocell medication plus standard chemotherapy, or standard chemotherapy alone (placebo). The study has two phases: first, a safety phase with 6 participants to make sure the combination is safe, followed by a larger phase with about 138 more participants. You will receive regular clinic visits and tests to monitor how well the treatment is working and to check for side effects throughout your participation.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States